Publication
Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (4)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 4
- cancerMelanomacivic_curation1.00
- drugDabrafenibcivic_curation1.00
- geneBRAFcivic_curation1.00
- variantBRAF V600Kcivic_curation1.00
Curated evidence
Evidence citing this paper (4)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 21343559
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| BRAF D594N1 | ||||||||
| Dabrafenib | Cutaneous MelanomaALIAS | Predictive | B | Supports Sensitivity Response | — | rejected | EID2813Patients were treated with a specific RAF inhibitor (dabrafenib), which improved overall survival of patients with BRAF mutations (P<0.003), compared to non-treated patients with BRAF mutations. Patie… (full text at CIViC) PMID 21343559 · Long et al., 2011 · Open in CIViC | civic |
| BRAF K601E1 | ||||||||
| Dabrafenib | Cutaneous MelanomaALIAS | Predictive | B | Supports Sensitivity Response | — | submitted | EID2812In a study of 197 metastatic melanoma patients, BRAF mutations were identified in 95 patients including V600E (n=70), V600K (n=19), K601E (n=1) and D594N (n=1). Patients were treated with a specific R… (full text at CIViC) PMID 21343559 · Long et al., 2011 · Open in CIViC | civic |
| BRAF V600E1 | ||||||||
| Dabrafenib | Melanoma | Predictive | B | Supports Sensitivity Response | — | submitted | EID2126Patients with BRAF mutations who were treated with the specific RAF inhibitor dabrafenib had an improved overall survival (P<0.003) compared to untreated patients with BRAF mutations. Patients harbori… (full text at CIViC) PMID 21343559 · Long et al., 2011 · Open in CIViC | civic |
| BRAF V600K1 | ||||||||
| Dabrafenib | Melanoma | Predictive | B | Supports Sensitivity Response | — | accepted | EID2505Patients were treated with a specific RAF inhibitor (dabrafenib), which improved overall survival of patients with BRAF mutations (P<0.003), compared to non-treated patients with BRAF mutations. Patie… (full text at CIViC) PMID 21343559 · Long et al., 2011 · Open in CIViC | civic |